Intarcia Therapeutics cuts 60 employees after FDA rejection

Privately-held Intarcia Therapeutics cut 60 employees and received a clinical hold for two marketing studies, four months after the FDA rejected its diabetes drug-eluting implant.

“Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports.”massdevice.com

• 1 source
• massdevice.comLatest Medical Device News on MassDeviceFink DensfordFeb 5, 2018

Summarized from public sources; check the original articles before acting on it.